Four pre-marketing clinical trials of biosimilar epoetin alfa were carried out on patients with CKD-related anemia showing no differences between biosimilar and reference product in achieving the Hb value target after 12 [9], 24 [10], 28 [11], or 56 [12] weeks of treatment. This evidence concerns the gene GSTM1 and anemia.